Targeted Nanomedicine in Cancer Therapy: Bridging Oncology and Nanoscience

##plugins.pubIds.doi.readerDisplayName## https://doi.org/10.70593/978-93-7185-359-0

Authors

Rahul Pal (ed)
Faculty of Medical, Paramedical and Allied Health Sciences, Department of Pharmacy, Jagannath University, 303901, Jaipur, Rajasthan, India
https://orcid.org/0000-0003-2062-2678
Shivang Shukla (ed)
Faculty of Medical, Paramedical and Allied Health Sciences, Department of Pharmacy, Jagannath University, 303901, Jaipur, Rajasthan, India
https://orcid.org/0009-0002-6395-6838
Shati Ghosh (ed)
Department of Pharmaceutics, International Institute of Pharmaceutical Science and Research, 741235, West Bengal, India.
https://orcid.org/0009-0008-2228-125X
Meena Devi (ed)
Department of Pharmacognosy, Gautam College of Pharmacy, Hamirpur, 177001, Himachal Pradesh, India.
https://orcid.org/0009-0000-2439-5711
Pratiksha Sharma (ed)
Department of Pharmaceutics, Gautam College of Pharmacy, Hamirpur, 177001, Himachal Pradesh, India.
https://orcid.org/0009-0006-2419-7532

Keywords:

Targeted Nanomedicine, Cancer Therapy, Nanoscience, Oncology, Cancer Disorders, Anatomy, Amyloidogenic

Synopsis

Targeted nanomedicine has emerged as a transformative approach in cancer therapy, offering precise, efficient, and patient-specific treatment strategies that bridge the disciplines of oncology and nanoscience. This book explores the design, development, and application of advanced nanocarrier systems—including liposomes, polymeric nanoparticles, dendrimers, micelles, and hybrid nanostructures—for targeted drug delivery in cancer management. Emphasis is placed on the ability of these nanosystems to enhance drug solubility, improve pharmacokinetics, minimize systemic toxicity, and achieve site-specific delivery through active and passive targeting mechanisms.

The volume highlights recent advancements in tumor biology, molecular targeting, and surface functionalization strategies, including ligand-receptor interactions, antibody conjugation, and stimuli-responsive systems. It also discusses the integration of diagnostic and therapeutic functionalities (theranostics), enabling real-time monitoring of treatment efficacy. Special attention is given to overcoming biological barriers, multidrug resistance, and tumor heterogeneity using smart and multifunctional nanoplatforms.

Furthermore, the book addresses translational challenges such as large-scale manufacturing, regulatory considerations, safety evaluation, and clinical validation of nanomedicines. Case studies and recent clinical developments provide insights into the current status and future potential of nanotechnology-driven cancer therapies. By connecting fundamental nanoscience with clinical oncology applications, this work serves as a comprehensive resource for researchers, academicians, and healthcare professionals aiming to advance precision medicine in oncology.

Chapters

References

Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2024.

Teli S, Shah TM. Design solid lipid nanoparticle solid lipid nanoparticle (SLNs) of dapagliflozin for enhanced oral bioavailability and controlled release in type 2 diabetes. African Journal of Biological Sciences. 2022;4(1):287-306.

International Agency for Research on Cancer. GLOBOCAN 2022: Cancer Today. Lyon: IARC; 2023.

Robbins SL, Kumar V, Abbas AK. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2021.

Pal, Rahul & Mandal, Raj & Shah, Tapaskumar & Singh, Anjali & Sahoo, Subhashree. (2026). Gastro-Retentive Drug Delivery Systems (GRDDs) as a Promising Strategy for Disease Targeting: A Comprehensive Review. Drug Delivery Letters. 10.2174/0122103031410778251206145139

Robbins SL, Kumar V, Abbas AK. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Philadelphia: Elsevier; 2021.

Downloads

Front Pages

Published

3 October 2025
Copyright (c) 2025 Anuradha Singh, Leemol Varghese, Mekala Keerthi priya, Maganti Sowmya, Muthineni Pradeep Kumar, Lingineni Mani Deepa Chandrika, Nalam Vineela Nirmala, Rajagiri Triveni, Koppula Sirisha, P. Thriveni, P. Spandana, M. Sri Vidya, N. Rithika, P. Akhila, Binita Ghosh, Sonal Sharma, Roshani Gupta, Anurag Basu, Binita Ghosh, Priya Singh, Nikhil Rajnani, Roshani Gupta, Anurag Basu, K. Sherstha, Nandita Sunil Ayanger, P. Likhithaa Reddy, R. Prasanthi, Yachi Sheth, Sana Fathima, P S Hritika, R. Prasanthi, Binita Ghosh, Nikhil Rajnani; Rahul Pal, Shivang Shukla, Shati Ghosh, Meena Devi, Pratiksha Sharma; Durgha Suresh, Tatikonda Sai Sri Pranathi, Buggana Siva Jyothi, Nikhil Rajnani, Bishal Debnath, Nikhil Rajnani, Mohd Basim, Dharmendra Singh Chauhan, Aliya Rehmani, Thatha Usha, Shaik Zaara, Soma Nandika, Polavarapu Renuka, Amena Madiha

Details about the available publication format: E-Book

E-Book

ISBN-13 (15)

978-93-7185-359-0

Details about the available publication format: Book (Paperback)

Book (Paperback)

ISBN-13 (15)

978-93-7185-006-3

How to Cite

Pal, R., Shukla, S. ., Ghosh, S., Devi, M., & Sharma, P. . (Eds.). (2025). Targeted Nanomedicine in Cancer Therapy: Bridging Oncology and Nanoscience. Deep Science Publishing. https://doi.org/10.70593/978-93-7185-359-0
Download Citation